INTRODUCTION {#S1}
============

The intestinal mucosal barrier surface is constantly exposed to food antigens, beneficial microbes, pathogens, and a multitude of other environmental stimuli ([@R33]). Innate lymphoid cells (ILCs) are known to contribute to innate and adaptive immune responses against these stimuli and play a critical role in maintaining barrier function and intestinal homeostasis ([@R1]; [@R2]; [@R3]; [@R15]; [@R31], [@R32]). ILCs are lineage-negative (Lin^-^), interleukin-7 (IL-7) receptor α-positive (CD127^+^), CD90^+^ innate immune cells that are widely distributed throughout the body, particularly enriched at the mucosal barriers ([@R1]; [@R2]; [@R3]; [@R15]). Group 3 ILCs (ILC3s) express the transcription factor RORγt and play pivotal roles in protecting against bacterial, viral, and fungal infections in the intestine by fortifying the epithelial barrier via rapid secretion of soluble factors, such as IL-22, lymphotoxin α, and IL-17A, as well as regulating CD4^+^ T cell responses toward intestinal commensal bacteria ([@R5]; [@R8]; [@R10], [@R11]; [@R13]; [@R16]; [@R26]). ILC3s are enriched in lymphoid tissues and at mucosal barrier surfaces, such as the intestinal tract, protecting against hazardous environmental stimuli together with other immune cells ([@R1]; [@R2]; [@R3]; [@R15]). Immune cells express various G-protein-coupled receptors (GPRs), including C-C motif chemokine receptors (CCRs), C-X-C motif chemokine receptors, and other GPRs, such as GPR183 and sphingosine-1-phosphate receptors, which regulate cell migration, accumulation, and distribution in tissues. Several chemokine receptors have been reported to control the accumulation of a subset of the ILC3s ([@R12]; [@R14]; [@R22]; [@R27]); however, the molecular mechanisms that regulate the accumulation, distribution, and function of the entire ILC3 population in lymphoid and mucosal tissues and their effects on anti-bacterial responses and tissue protection are incompletely defined.

GPR183 (also known as EBI2) is a Gα-coupled seven-transmembrane chemotactic receptor. It is highly expressed on follicular B cells, CD4^+^ dendritic cells (DCs), and CD4^+^ T cells but is downregulated on germinal center (GC) B cells in secondary lymphoid organs and controls cell migration to achieve efficient antibody responses and CD4^+^ T cell responses ([@R6], [@R7]; [@R18]; [@R24]; [@R34]; [@R35]). GPR183 ligand, 7α,25-dihydroxycholesterol (7α,25-OHC), is produced by stromal cells residing in the interfollicular regions of lymph nodes (LNs) and the bridging channels of the spleen ([@R9]; [@R21]; [@R35]). GPR183 expressed on CD4+ ILC3s (also termed as lymphoid tissue inducer cells \[LTis\]) controls their migration and the formation of colonic tertiary lymphoid organs ([@R4]). However, whether GPR183 and 7α,25-OHC control the accumulation, distribution, and tissue-protective function of ILC3s in the gut-associated lymphoid tissues and in the intestinal lamina propria (LP) has not been examined.

In this study, we demonstrate that ILC3s isolated from the mesenteric LNs (mLNs) and intestinal LP express GPR183 and intestinal ILC3s migrate toward 7α,25-OHC *in vitro*. Quantitative PCR (qPCR) analysis indicated 7α,25-OHC production by gut stromal cells, and genetic deletion of GPR183 or 7α,25-OHC resulted in a disorganized accumulation of ILC3s in the subcap-sular sinus of the mLNs and reduced ILC3 accumulation in the intestine. The regulation of ILC3 accumulation in the intestine by GPR183 was ILC3 intrinsic and was required for optimal IL-22 production and protective immunity against the enteric bacterium, *Citrobacter rodentium (C. rodentium)*. Taken together, these data reveal a previously unrecognized role of the GPR183-7α,25-OHC pathway in regulating ILC3-dependent immunity to enteric bacterial infection.

RESULTS {#S2}
=======

GPR183 Is Constitutively Expressed on ILC3s and Mediates Migration toward 7α,25-OHC {#S3}
-----------------------------------------------------------------------------------

To study the pathways that regulate the distribution and accumulation of ILC3s in lymphoid and mucosal tissues *in vivo*, we undertook an unbiased analysis of molecules associated with these processes by RNA sequencing (RNA-seq). Among the genes listed in the gene ontology (GO) term "lymphocyte chemo-taxis,'' *Gpr183* was the most abundant gene expressed in intestinal LP ILC3s ([Figure S1A](#SD1){ref-type="supplementary-material"}). To further examine this, we sorted ILC subsets from intestinal LP cells as well as mLN cells harvested from *Rorc(γt)*^*Gfp*^ mice and analyzed the expression of *Gpr183* mRNA by quantitative PCR. Consistent with the RNA-seq data, intestinal CCR6^+^ ILC3s and CCR6^-^ lLC3s and mLN ILC3s had high *Gpr183* mRNA expression, and the expression in intestinal CCR6^+^ ILC3s was higher than in ILC1s and ILC2s ([Figure 1A](#F1){ref-type="fig"}). To examine GPR183 protein expression, we employed *Gpr183*^*LacZ/+*^ reporter mice, which were generated by replacing the *Gpr183* coding region with the *LacZ* gene, and we could detect LacZ expression in non-GC B cells, but not in GC B cells ([Figure S1B](#SD1){ref-type="supplementary-material"}). We confirmed the LacZ expression in mLN and small intestinal (SI) ILC3s ([Figure 1B](#F1){ref-type="fig"}; gating strategy in [Figure S1C](#SD1){ref-type="supplementary-material"}). We also detected GPR183 protein staining on CD45^+^Lin^-^CD127^+^CD117^+^CRTH2^-^ cells, which are ILC3s in human ileal LP and ILC precursors in peripheral blood mononuclear cells (PBMCs) ([@R20]) from healthy donors ([Figures 1C and 1D](#F1){ref-type="fig"}; gating strategy in [Figure S1D](#SD1){ref-type="supplementary-material"}). Collectively, these data show that murine and human ILC3s express GPR183.

Given that GPR183 is a chemotactic receptor expressed on follicular B cells, CD4^+^ T cells, and DCs, mediating their migration toward the GPR183 ligand 7α,25-OHC ([@R6], [@R7]; [@R18]; [@R24]; [@R34]; [@R35]), we tested whether ILC3s migrate toward 7α,25-OHC *in vitro*. We performed transwell migration assays with SILP cells from wild-type (WT) mice and *Gpr183*^*−/−*^mice. WT ILC3s migrated toward 7α,25-OHC *in vitro*, whereas *Gpr183*^*−/−*^ ILC3s did not, indicating that GPR183 regulates ILC3s migration toward 7α,25-OHC ([Figure 1E](#F1){ref-type="fig"}).

CH25H and CYP7B1 Are Expressed in Intestinal Stromal Cells {#S4}
----------------------------------------------------------

Cholesterol 25-hydroxylase (CH25H) and oxysterol 7α-hydroxy-lase (CYP7B1), which are enzymes required for the biosynthesis of GPR183 ligand 7α,25-OHC, are highly expressed in spleen and LN stromal cells ([@R9]; [@R21]; [@R35]). To determine whether CH25H and CYP7B1 are also expressed in intestinal stromal cells, we fractionated mouse SI into epithelial, LP leukocyte (LPL), and stromal compartments and measured the relative expression of *Ch25h* and *Cyp7b1* mRNA in each compartment by qPCR. Expression of *Ch25h* and *Cyp7b1* was higher in the stromal compartment compared to epithelial and LPL compartments of the SI ([Figure 1F](#F1){ref-type="fig"}), suggesting 7α,25-OHC production by intestinal stromal cells. Together with previous reports ([@R4]; [@R35]), these data indicate that the interaction of GPR183 expressed on ILC3s and 7α,25-OHC produced by stromal cells in mLNs and the intestine may control the accumulation of ILC3s in these organs.

GPR183 and 7α,25-OHC Control the Distribution of ILC3s in mLNs {#S5}
--------------------------------------------------------------

To examine the effect of GPR183 deficiency on ILC3s at steady state *in vivo*, we analyzed ILC3s from WT mice and *Gpr183*^*−/−*^ mice using flow cytometry. Percentages of RORγt^+^ ILC3s within the total ILC population (CD45^+^Lin^-^CD90^+^CD127^+^; refer to the gating strategy in [Figure S2A](#SD1){ref-type="supplementary-material"}) were significantly increased in the mLNs of *Gpr183*^*−/−*^ mice, along with increased ILC3 numbers compared to WT mice ([Figures 2A and 2B](#F2){ref-type="fig"}). The frequencies and numbers of NKp46^+^RORγt^-^ ILC1s and GATA-3^+^ ILC2s were reduced in *Gpr183*^*−/−*^ mice compared to WT mice ([Figures S2B and S2C](#SD1){ref-type="supplementary-material"}). *Ch25h*^*−/−*^ mice that have defective 7α,25-OHC production ([@R9]; [@R21]) exhibited increased ILC3s, reduced ILC1s, and comparable ILC2s in the mLNs compared to WT mice at steady state (Figures [2C, 2D](#F2){ref-type="fig"}, [S2D, and S2E](#SD1){ref-type="supplementary-material"}).

Previous studies identified that the localization of GPR183-expressing T cells, B cells, and DCs within lymphoid tissues is regulated by 7α,25-OHC produced from tissue stromal cells ([@R6], [@R7]; [@R9]; [@R18]; [@R21]; [@R24]; [@R34]; [@R35]). To examine whether GPR183 regulates the localization of ILC3s in mLNs, we stained mLN sections from WT mice and *Gpr183*^*−/−*^ mice with anti-RORγt, CD3ε, and CD127 antibodies to visualize ILC3s ([Figure 2E](#F2){ref-type="fig"}). Serial sections were stained for B220 or MAdCAM-1 to examine the position of follicles and the subcapsular sinuses ([Figures 2F and 2G](#F2){ref-type="fig"}). There was no overt difference in the structure of follicles and T cell areas in mLNs from *Gpr183*^*−/−*^ mice compared to WT mice, which is consistent with the previous report ([@R24]). RORγt^+^CD3ε^-^CD127^+^ ILC3s were found predominantly in the interfollicular areas of WT mLN sections, which is consistent with published results ([@R11]; [@R22]). A significantly higher proportion of the *Gpr183*^*−/−*^ ILC3s were found in the outer regions of the in-terfollicular areas rather than their normal localization in mLNs compared to that of the WT ILC3s ([Figures 2E-2H](#F2){ref-type="fig"}; refer to [Figure S2F](#SD1){ref-type="supplementary-material"} for the definition of inner and outer regions). Similarly, staining of mLN sections from WT mice and *Ch25h*^*−/−*^ mice showed more ILC3s localized in the outer regions of the interfollicular areas of *Ch25h*^*−/−*^ mLNs compared to WT mLNs (Figures [2I, 2J](#F2){ref-type="fig"}, and [S2F](#SD1){ref-type="supplementary-material"}). Consistent with the flow cytometry data ([Figures 2A and 2B](#F2){ref-type="fig"}), more ILC3s were found in the interfollicular areas in the *Gpr183*^*−/−*^ mLNs compared to WT ([Figure 2K](#F2){ref-type="fig"}). We also examined the Peyer's patches (PPs) and found increased ILC3s in the *Gpr183*^*−/−*^ PPs compared to WT ([Figure S2G](#SD1){ref-type="supplementary-material"}). Immunofluorescent staining of PP sections revealed accumulation of ILC3s in between the follicle and the T cell area in the luminal side of *Gpr183*^*−/−*^ mice ([Figure S2H](#SD1){ref-type="supplementary-material"}). Collectively, these results suggest that GPR183 and 7α,25-OHC control the distribution and accumulation of ILC3s in the mLNs and PPs. Notably, ILC3s from *Gpr183*^*−/−*^ mice had comparable expression of CCR7 and CCR9 but significantly lower expression of integrin α4β7, which mediates cell trafficking to the intestine ([@R14]), compared to ILC3s from WT mice (Figures [2L](#F2){ref-type="fig"} and [S2I](#SD1){ref-type="supplementary-material"}).

GPR183 and 7α,25-OHC Regulate ILC3 Accumulation in the Intestine {#S6}
----------------------------------------------------------------

Given that GPR183 appears to regulate migration of intestinal ILC3s ([Figure 1E](#F1){ref-type="fig"}) and expression of gut-tropic integrin expression ([Figure 2L](#F2){ref-type="fig"}), we analyzed the accumulation of ILC3s in the SILP of *Gpr183*^*−/−*^ mice and WT mice. In contrast to mLNs, RORγt^+^ ILC3s, including both the NKp46^+^ and CCR6^+^ ILC3 subsets, were significantly reduced in *Gpr183*^*-l-*^ SILP compared to WT at steady state ([Figures 3A-3D](#F3){ref-type="fig"}). As intestinal stromal cells are potential producers of 7α,25-OHC ([Figure 1F](#F1){ref-type="fig"}; [@R4]), we also examined the SILP of *Ch25*^*−/−*^ mice and found fewer ILC3s in *Ch25*^*−/−*^ mice compared to WT mice ([Figures 3E-3H](#F3){ref-type="fig"}). To examine whether GPR183 regulates the localization of ILC3s in the SI, we crossed *Gpr183*^*−/−*^ mice with *Rorc(γt)*^*Gfp*^ mice and stained the SI sections with anti-GFP, CD3ε, and B220 antibodies ([Figure 3I](#F3){ref-type="fig"}). WT and *Gpr183*^*−/−*^ GFP ^+^CD3ε^-^ ILC3s were similarly scattered in the LP, but *Gpr183*^*−/−*^ mice had fewer cryptopatches (CPs) compared to WT mice, which is consistent with the flow cytometry data ([Figures 3A, 3B, and 3J](#F3){ref-type="fig"}). When we analyzed the colon LP at steady state, the numbers and proportions of ILCs were comparable between WT and *Gpr183*^*−/−*^ mice or *Ch25h*^*−/−*^ mice ([Figures S3A-S3D](#SD1){ref-type="supplementary-material"}), but *Gpr183*^*−/−*^ mice had fewer CPs and isolated lymphoid follicles in the colon compared to WT mice ([Figures S3E and S3F](#SD1){ref-type="supplementary-material"}). Taken together, these results suggest that, through binding to 7α,25-OHC produced by intestinal stromal cells, GPR183 promotes the accumulation of ILC3s in the intestine.

ILC3-Intrinsic Expression of GPR183 Controls Their Accumulation in the Intestine and mLNs {#S7}
-----------------------------------------------------------------------------------------

To test whether the regulation of ILC3 accumulation in the intestine and mLNs by GPR183 is ILC3-intrinsic, we generated mixed bone marrow (BM) chimera mice by transferring congenically labeled WT or *Gpr183*^*−/−*^ cells (CD45.2^+^) mixed with WT BM cells (CD45.1^+^CD45.2^+^) into lethally irradiated recipient mice (CD45.1^+^). After 8 weeks of reconstitution, we examined the ratios of WT or *Gpr183*^*−/−*^ CD45.2^+^ cells to internal control WT CD45.1^+^CD45.2^+^ cells within ILC3 populations. Compared to WT CD45.2^+^ BM mixed with WT CD45.1^+^CD45.2^+^ BM chimera (WT:WT mice), *Gpr183*^*−/−*^ CD45.2^+^ BM mixed with WT CD45.1^+^CD45.2^+^ BM chimera (*Gpr183*^*−/−*^:WT mice) had significantly reduced ratios of CD45.2^+^ ILC3s to CD45.1^+^CD45.2^+^ ILC3s in the SI (Figures [3K](#F3){ref-type="fig"} and [S3G](#SD1){ref-type="supplementary-material"}). We also observed smaller ILC3 percentages in *Gpr183*^*−/−*^ CD45.2^+^ cells compared to that in WT CD45.1^+^CD45.2^+^ cells in total SI ILCs within each Gpr183^−/−^:WT mice ([Figure S3H](#SD1){ref-type="supplementary-material"}; 8.3 ± 0.1 versus 13.4 ± 0.9; mean ± SEM; p \< 0.01). Meanwhile, *Gpr183*^*−/−*^*:WT* mice exhibited significantly increased ratios of CD45.2^+^ ILC3s to CD45.1^+^CD45.2^+^ ILC3s in the mLNs compared to WT:WT mice ([Figure 3K](#F3){ref-type="fig"}).

The expression of the proliferation marker Ki67 was comparable in CD45.1^+^CD45.2^+^ ILC3s (WT) and CD45.2^+^ ILC3s (WT or *Gpr183*^*−/−*^) in both chimeras ([Figure 3L](#F3){ref-type="fig"}). Therefore, GPR183 appears to regulate the accumulation, but not the proliferation, of ILC3s in the intestine and mLNs in a cell-intrinsic manner. Moreover, *Gpr183*^*−/−*^*:WT* mice exhibited increased ratios of CD45.2^+^ cells in the ILC1 gate and comparable ratios of ILC2s compared to WT:WT mice, suggesting that the reduced ILC1s and ILC2s in *Gpr183*^*−/−*^ mLNs was secondary to the cell-intrinsic effect on ILC3s ([Figure S3I](#SD1){ref-type="supplementary-material"}).

GPR183 Is Required for ILC3-Mediated Protective Immunity following Enteric Bacterial Infection {#S8}
----------------------------------------------------------------------------------------------

ILC3s are critical in promoting innate immunity to *C. rodentium* infection through producing IL-22, which triggers the secretion of anti-microbial peptides from intestinal epithelial cells ([@R26]; [@R28]; [@R30]; [@R36]). Considering that GPR183 deficiency hampers ILC3 accumulation in the intestine, we sought to test whether GPR183 regulates ILC3-mediated innate immunity against *C. rodentium* infection. Similar to the SI of *Gpr183*^*−/−*^ mice ([Figures 3A-3D](#F3){ref-type="fig"}), percentages and numbers of ILC3s were significantly reduced in the SI and the colon of *Rag1*^*−/−*^*Gpr183*^*−/−*^ mice compared to *Rag1*^*−/−*^ mice at steady state ([Figures S4A-S4D](#SD1){ref-type="supplementary-material"}). Numbers of NKp46^+^ ILC3s and CCR6^+^ ILC3s were both significantly reduced in *Rag1*^*−/−*^*Gpr183*^*−/−*^ mice ([Figures S4E and S4F](#SD1){ref-type="supplementary-material"}). At 8 days after *C. rodentium* infection, *Rag1*^*−/−*^*Gpr183*^*−/−*^ mice also exhibited significantly reduced frequencies and numbers of ILC3s in the SI and the colon compared to *Rag1*^*−/−*^ mice (Figures [4A, 4B](#F4){ref-type="fig"}, [S4G, and S4H](#SD1){ref-type="supplementary-material"}). Similar to steady state, numbers of NKp46^+^ ILC3s and CCR6^+^ ILC3s in the SI were both significantly reduced in infected *Rag1*^*−/−*^*Gpr183*^*−/−*^ mice compared to *Rag1*^*−/−*^ mice ([Figures S4I and S4J](#SD1){ref-type="supplementary-material"}). The percentages of Ki67^+^ cells in intestinal ILC3s were comparable between *Rag1*^*−/−*^ mice and *Rag1*^*−/−*^ *Gpr183*^*−/−*^ mice, suggesting that the proliferation of ILC3s during infection is not regulated by GPR183 (Figures [4C](#F4){ref-type="fig"} and [S4K](#SD1){ref-type="supplementary-material"}). We next examined whether the IL-22-producing capacity of ILC3s was regulated by GPR183 expression. Notably, both *Rag1*^*−/−*^ and *Rag1*^*−/−*^*Gpr183*^*−/−*^ ILC3s contained similar percentages of IL-22^+^ cells, suggesting that GPR183 deficiency does not affect the capability of IL-22 production in ILC3s (Figures [4D](#F4){ref-type="fig"}, [S4L, and S4M](#SD1){ref-type="supplementary-material"}). However, numbers of IL-22-producing ILC3 were significantly reduced in *Rag1*^*−/−*^*Gpr183*^*−/−*^ compared to *Rag1*^*−/−*^ mice, due to lower total numbers of ILC3 in *Rag1*^*−/−*^*Gpr183*^*−/−*^ mice (Figures [4E](#F4){ref-type="fig"} and [S4N](#SD1){ref-type="supplementary-material"}).

In accordance with reduced numbers of IL-22-producing ILC3s, *Rag1*^*−/−*^*Gpr183*^*−/−*^ mice exhibited significantly more severe colonic crypt hyperplasia, colonic shortening, and more severe loss of body weight compared to *Rag1*^*−/−*^ mice, indicating impaired ILC3-dependent innate immunity and tissue protection in *Rag1*^*−/−*^*Gpr183*^*−/−*^ mice ([Figures 4F-4H](#F4){ref-type="fig"}). Lipocalin 2 *(Lcn2)* mRNA expression was higher in *Rag1*^*−/−*^*Gpr183*^*−/−*^ mice, which is consistent with exacerbated inflammation compared to *Rag1*^*−/−*^ mice ([Figure 4I](#F4){ref-type="fig"}). Moreover, *Rag1*^*−/−*^*Gpr183*^*−/−*^ mice exhibited a reduced survival rate following infection compared to *Rag1*^*−/−*^ mice ([Figure 4J](#F4){ref-type="fig"}). Given the importance of IL-22 in tissue protection following bacterial infection ([@R26]; [@R28]; [@R30]; [@R36]), these results suggest that GPR183 regulates anti-bacterial responses and tissue protection through facilitating the accumulation of IL-22-producing ILC3s in the intestine. Taken together, these data identify a crosstalk between GPR183-expressing ILC3s and intestinal stromal cells that express 7α,25-OHC, which is required for optimal ILC3 responses and host protective immunity against enteric bacterial infection.

DISCUSSION {#S9}
==========

Mucosal barriers are constitutively challenged by various stimuli, and the homeostasis of mucosal barriers both at steady state and upon challenge are maintained by tissue-resident immune cells ([@R17]; [@R23]). ILC3s are found in lymphoid tissues and are enriched in the intestine, where they play critical roles in regulating adaptive immune responses against commensal bacteria, as well as in innate immunity against enteric bacterial infections ([@R10], [@R11]; [@R25]; [@R26]; [@R28]; [@R29]; [@R30]). Although the mechanisms ILC3s employ to control infections and promote tissue repair continue to be defined ([@R26]; [@R28]; [@R30]), our understanding of how the accumulation, distribution, and tissue-protective function of ILC3s in the intestine and its associated lymphoid organs are controlled remained limited. [@R4] recently reported that CD4^+^ LTi-like ILC3s express GPR183 that controls cell migration and formation of solitary intestinal lymphoid tissues in the colon and enhances IL-22 production by ILC3s in the colon at steady state. In the current study, we demonstrate that GPR183 is expressed on murine and human ILC3s and that GPR183 and its ligand 7α,25-OHC regulate the accumulation and distribution of ILC3s in lymphoid tissues and the intestine, and consequently, GPR183 controls ILC3-dependent innate immunity and tissue protection following enteric bacterial infection. We also identify GPR183-dependent accumulation of IL-22-producing ILC3s in the intestine following *C. rodentium* infection. Of note, enhanced IL-22 production by ILC3s was not detectable, possibly due to heightened inflammation elicited by the bacterial infection.

ILC3s reside in the interfollicular areas of the mLNs, where they present commensal bacterial antigen through major histocompatibility complex class II and prevent CD4^+^ T cell-induced chronic intestinal inflammation toward commensal bacteria ([@R11]). In this study, we show that GPR183 controls the distribution of ILC3s in mLNs. GPR183-deficient ILC3s accumulated in the outer regions of the inter-follicular areas, which are close to the subcapsular sinuses. DCs migrate into the LNs via the lymph through subcapsular sinuses and then move to the paracortex where they interact with helper T cells ([@R19]). This pathway is regulated by CCR7, a molecule that also controls the accumulation of ILC3s to LNs ([@R19]; [@R22]). Similarly, ILC3s migrate from other organs, such as the intestine ([@R22]), and enter the LNs through subcapsular sinuses. In the context of GPR183 deficiency, ILC3s cannot migrate into the interfollic-ular areas because they fail to respond to the ligand expressed in the inner regions of the interfollicular areas and hence are sequestered in the subcapsular sinuses. As GPR183 plays such important roles in regulating the distribution and function of ILC3s in both lymphoid and non-lymphoid tissues, GPR183 itself and its oxysterol ligand-producing pathway could be potential therapeutic targets for controlling and regulating ILC3 functions in multiple infectious and inflammatory diseases.

EXPERIMENTAL PROCEDURES {#S10}
=======================

Further details and an outline of resources used in this work can be found in [Supplemental Experimental Procedures](#SD1){ref-type="supplementary-material"}.

Mice {#S11}
----

C57BL/6 (Jax 664), *Gpr183*^*LacZ/+*^ (Jax 26443), *Ch25h*^*−/−*^ (Jax 16263), CD45.1 (Jax 2014), and *Rag1*^*−/−*^ (Jax 2216) mice were purchased from The Jackson Laboratory. *Rorc(γt)*^*Gfp*^ was provided by Dr. G. Eberl (Institut Pasteur, France). Breeding of *Gpr183*^*LacZ/+*^ to homozygosity resulted in Gpr183-deficient (*Gpr183*^*LacZ/LacZ*^) mice referred to as *Gpr183*^*−/−*^ throughout the manuscript. Sex-and age-matched WT and transgenic mice between 6 and 16 weeks of age were co-housed and used for experiments. All mice were maintained under specific pathogen-free conditions and were used in accordance with the Institutional Animal Care and Use Committee guidelines at Weill Cornell Medical College.

Isolation and Flow Cytometry Staining of Human ILC3s {#S12}
----------------------------------------------------

Intestinal biopsies from the terminal ileum were obtained, processed, and viably cryopreserved as previously described ([@R10],[@R11]). Following thawing, cells were stained for CD3 (UCHT1), CD19(HIB19),CD11c(S-HCL-3), CD11b (M1/70), CD14 (M5E2) as line age markers, and CD45 (HI30), CRTH2 (BM16), CD127 (A019D5), CD117 (104D2), GPR183 (SA313E4), or mouse immunoglobulin G2a (IgG2a), κ (MOPC-173) was used as isotype control. Dead cells were excluded with the Live/Dead Fixable Aqua Dead Cell Stain Kit. ILCs were gated as CD45^+^Lin^-^CD127^+^, and ILC3s were gated as CD45^+^Lin^-^CD127^+^CRTH2^-^CD117^+^. PBMCs were isolated from buffy coats (New York Blood Center) with a Ficoll-Paque PLUS (GE Healthcare) gradient. All samples were cryopreserved and stored in liquid nitrogen. For staining ILC precursorsfrom PBMCs, cells were incubated with FcR Blocking Reagent (Miltenyi Biotec) and subsequentlystained forCD3(UCHT1), CD123(6H6), CD5 (UCHT2), FcεRI (AER-37), CD11c (S-HCL-3), CD11b(M1/70), CD34 (581), CD14 (HCD14) as lineage markers and CD19 (HIB19), CD45 (HI30), CRTH2 (BM16), CD94 (DX22), CD127 (A019D5), and CD117 (104D2). For surface receptor expression analysis, anti-GPR183 (SA313E4) or mouse IgG2a, κ isotype control (MOPC-173) was used. Dead cells were excluded with the Live/Dead Fixable Aqua Dead Cell Stain Kit. ILC precursors were gated as CD45^+^Lin^-^CD19^-^CD94^-^CD127^+^CRTH2^-^CD117^+^. All antibodies were purchased from eBioscience, BioLegend, or BD Bioscience.

Quantification and Statistical Analysis {#S13}
---------------------------------------

Statistical tests were performed with Prism (GraphPad). Unless specifically indicated otherwise, Student's t tests were used to compare endpoint means of different groups. Error bars depict the SEM. For the comparison of Kaplan-Meier survival curves, log rank (mantel-Cox) test was used. \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, and \*\*\*\*p \< 0.0001.
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![GPR183 Is Expressed on ILC3s and Regulates ILC3 Migration\
(A) qPCR analysis of *Gpr183* transcript abundance in indicated sort-purified cell populations presented relative to *Hprt1*. Each symbol represents sample from one mouse or pooled from 2 or 3 mice. Fo B, follicular B cells; GC B, germinal center B cells. \*p \< 0.05 and \*\*\*\*p \< 0.0001 by one-way ANOVA with Dunnett's multiple comparison.\
(B) LacZ staining (conversion of the fluorescent LacZ substrate fluorescein di-β-D-galactopyrano-side \[FDG\]) indicating GPR183 expression on ILC3s from mLNs and SILP. Data are representative of 2 independent experiments.\
(C) Flow cytometry histograms of anti-GPR183 staining on ILC3s (red line), total ILCs (blue line), and isotype control staining on total ILCs (shaded gray) from human terminal ileum. Data are representative of 5 donors.\
(D) Flow cytometry histograms of anti-GPR183 staining (red line) and isotype control staining (shaded gray) on ILC precursors from human PBMCs. Data are representative of 4 donors.\
(E) *In vitro* migration of ILC3s toward 7α,25-OHC. Data are representative of 2 independent experiments. \*\*p \< 0.01.\
(F) qPCR analysis of 7α,25-OHC-producing enzymes *Ch25h* and *Cyp7b1* transcript abundances in fractionated SI samples from WT mice, presented relative to *Hprt1*. LPL, lamina propria leukocyte.\
Each symbol represents one mouse unless specifically indicated. Data are mean ± SEM. See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1500497-f0002){#F1}

![Disorganized ILC3 Distribution in the mLNs of *Gpr183*^*−/−*^ and *Ch25h*^*−/−*^ Mice\
(A and B) Population frequencies (A) and numbers\
(B) of RORγt^+^ ILC3s in the mLNs of WT and *Gpr183*^*−/−*^ mice at steady state, gated on CD45^+^Lin^-^CD127^+^CD90^+^ cells. Data are representative of 3 independent experiments. \*\*p \< 0.01, \*\*\*p \< 0.001.\
(C and D) Population frequencies (C) and numbers (D) of RORγt^+^ ILC3s in the mLNs of WT and *Ch25h*^*−/−*^ mice at steady state, gated on CD45^+^Lin^-^CD127^+^CD90^+^ cells. Data are representative of 3 independent experiments. \*\*p \< 0.01, \*\*\*\*p \< 0.0001.\
(E-G) Representative images of mLN sections of WT and *Gpr183*^*−/−*^ mice stained for RORγt, CD127 and DAPI together with CD3ε (E), B220(F) or MAdCAM-1 (G). Follicles, or F, are designated by dashed lines. The scale bars represent 50 μm.\
(H) Percentages of ILC3s localized in the outer regions over ILC3s localized in the interfollicular areas between follicles in mLN sections of WT and *Gpr183*^*−/−*^ mice. Twenty-three interfollicular areas in15 mLNs from 3 WT mice and 21 interfollicular areas in 15 mLNs from 3 *Gpr183*^*−/−*^ mice were examined. \*\*\*p \< 0.001. (I and J) Representative images of ILC3 distribution (I) and percentages of ILC3s localized in the outer regions (J) in mLN sections of WT and *Ch25h*^*−/−*^ mice. Ten interfollicular areas in 10 mLNs from 2 WT mice and 14 interfollicular areas in 10 mLNs from 2 *Ch25h*^*−/−*^ mice were examined. The scale bars represent 100 μm. In\
(J), \*p \< 0.05.\
(K) Numbers of ILC3s in interfollicular areas (inner and outer regions) in mLN sections of WT and *Gpr183*^*−/−*^ mice. See Figures 2E-2H legend for details. \*p \<0.05, \*\*p \< 0.01.\
(L) The enumeration of anti-a4b7 geometric mean fluorescence intensity (GMFI) on mLN ILC3s of WT and *Gpr183*^*−/−*^ mice. Data are representative of 3 independent experiments. \*p \< 0.05.\
Each symbol represents one mouse (A-D and L) or one region (H, J, and K). Data are mean ± SEM. See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1500497-f0003){#F2}

![Defective ILC3 Accumulation in the SI of *Gpr183*^*−/−*^ and *Ch25h*^*−/−*^ Mice\
(A-D) Population frequencies (A) and numbers (B) of RORγt^+^ ILC3s and numbers of NKp46^+^RORγt^+^ ILC3s (C) and CCR6^+^RORγt^+^ ILC3s (D) in the SI of WT and *Gpr183*^*−/−*^ mice at steady state, gated on CD45^+^Lin^-^ CD127^+^CD90^+^ cells. Data are representative of 3 independent experiments. \*\*p \< 0.01.\
(E-H) Population frequencies (E) and numbers (F) of RORγt^+^ ILC3s and numbers of NKp46^+^RORγt^+^ ILC3s (G) and CCR6^+^RORγt^+^ ILC3s (H) in the SI of WT and *Ch25h*^*−/−*^ mice at steady state, gated on CD45^+^Lin^-^CD127^+^CD90^+^ cells. Data are pooled from 2 experiments. In (E) and (F), \*p \< 0.05. In (G), \*\*p \< 0.01.\
(I)Representative images of ILC3 distribution and CPs in SI sections of WT and *Gpr183*^*−/−*^ mice. The scale bars represent 500 μm.\
(J) Numbers of CPs in SI sections of WT and *Gpr183*^*−/−*^ mice. \*p \< 0.05.\
(K) Ratios of CD45.2^+^ ILC3s to CD45.1^+^CD45.2^+^ ILC3s in the SI and mLNs of mixed BM chimera mice with indicated genotypes. Data are representative of 3 independent experiments. \*\*p \< 0.01, \*\*\*p \< 0.001. See also [Figure S3G](#SD1){ref-type="supplementary-material"}.\
(L) Frequencies of Ki67-expressing ILC3s in the SI of WT:WT (left) and *Gpr183*^*−/−*^:WT (right) BM chimera mice. Data are representative of 3 independent experiments.\
Each symbol represents one mouse. Data are mean ± SEM. See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1500497-f0004){#F3}

![GPR183 Is Required for ILC3-Mediated Protection against *C. rodentium* Infection\
(A-H) *Rag1*^*−/−*^ and *Rag1*^*−/−*^*Gpr183*^*−/−*^ mice were infected with *C. rodentium* and were analyzed 8 (A-E and I) and 10(F-H) days post-infection (d.p.i.).\
(A and B) Population frequencies (A) and numbers (B) of ILC3s in the colon LP, gated on CD45^+^Lin^-^CD127^+^CD90^+^ cells. \*\*p \< 0.01, \*\*\*p \< 0.001.\
(C) Frequencies of Ki67-expressing colonic ILC3s. (D and E) Frequencies (D) and numbers (E) of IL-22-producing colonic ILC3s following IL-23 restimulation. In (E), \*p \< 0.05.\
(F) Representative H&E staining sections of colon (left) and enumeration of the crypt length (right). The scale bars represent 100 μm.\
(G-J) Colon length (G), changes in body weight (H), *Lcn2* mRNA expression (I), and survival (J) of infected *Rag1*^*−/−*^ and *Rag1*^*−/−*^*Gpr183*^*−/−*^ mice. Body weight is presented relative to initial weight, set as 100%. Survival data are pooled from 2 experiments (8 mice per group). \*p \< 0.05, \*\*p \< 0.01. All data are representative of 2 independent experiments unless stated. Each symbol represents one mouse. Data are mean ± SEM. See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1500497-f0005){#F4}

###### Highlights

-   ILC3s from mouse mesenteric lymph nodes and mouse and human intestine express GPR183

-   GPR183 and its ligand 7α,25-OHC promote ILC3 migration *in vitro*

-   GPR183 and 7α,25-OHC regulate the accumulation and function of ILC3s *in vivo*

-   GPR183 is required for ILC3-mediated immunity against enteric bacterial infection
